Brookfield Asset Management Inc. Vertex Pharmaceuticals Inc Transaction History

Brookfield Asset Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	BUY	$314.42 - $351.91 $7.11 Million - $7.96 Million	22,614 Added 1944.45%	23,777 $8.37 Million
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $7.11 Million - $7.96 Million	22,614 Added 1944.45%	23,777 $8.37 Million
Q1 2023 Sep 25, 2023	SELL	$283.23 - $323.1 $6.4 Million - $7.31 Million	-22,614 Reduced 95.11%	1,163 $366,000
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $329,396 - $375,765	1,163 New	1,163 $366,000
Q2 2022 Nov 16, 2022	BUY	$234.96 - $292.55 $8.09 Million - $10.1 Million	34,445 New	34,445 $9.71 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $1.94 Million - $2.41 Million	-8,252 Reduced 19.33%	34,445 $9.71 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $5.28 Million - $6.66 Million	29,816 Added 231.47%	42,697 $9.38 Million
Q3 2021 Nov 16, 2021	BUY	$181.39 - $202.99 $732,634 - $819,876	4,039 Added 45.68%	12,881 $2.34 Million
Q2 2021 Aug 17, 2021	BUY	$187.49 - $221.1 $1.66 Million - $1.95 Million	8,842 New	8,842 $1.78 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.